KRAS and cancer: This pattern of staining is consistent with the observations from other groups, such as a study of 1030 stage 2–3 CRC patients by Edwards et al. In this patient cohort discrete cytoplasmic staining (termed punctate in this paper) was associated with poor cancer-specific survival, and KRAS mutation.